Бренд ASIDE: A PHASE IIIB, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABATACEPT ADMINISTERED SUBCUTANEOUSLY AND INTRAVENOUSLY IN, основанный в 2010 (Соединенные Штаты), на 496 дочерних брендов а также 17479 конкурирующих брендов. ASIDE: A PHASE IIIB, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABATACEPT ADMINISTERED SUBCUTANEOUSLY AND INTRAVENOUSLY IN - это торговая марка BRISTOL-MYERS SQUIBB COMPANY, котирующаяся на фондовой бирже New York. ASIDE: A PHASE IIIB, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABATACEPT ADMINISTERED SUBCUTANEOUSLY AND INTRAVENOUSLY IN относится к бизнес-сектору Производители лекарств.
Все новости 
BRISTOL-MYERS SQUIBB COMPANY
(ASIDE: A PHASE IIIB, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABATACEPT ADMINISTERED SUBCUTANEOUSLY AND INTRAVENOUSLY IN)
